Bupropion SR vs placebo for smoking cessation in health care professionals

Am J Health Behav. May-Jun 2005;29(3):240-9. doi: 10.5993/ajhb.29.3.5.

Abstract

Objective: To evaluate bupropion SR for smoking cessation in physicians and nurses.

Methods: This double-blind prospective 26-center, 12-country trial randomized 687 subjects to smoking cessation counselling with bupropion SR or placebo for 7 weeks. The participants were followed for 52 weeks.

Results: Bupropion SR was superior to placebo (50% vs 40%, P=0.013) on the 4-week primary outcome variable. Due to a high placebo response in this health care population, statistical differences were not maintained after treatment was discontinued.

Conclusions: Bupropion SR is effective and well tolerated in health care professionals. Relapse prevention measures are needed to attain long-term abstinence.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Bupropion / administration & dosage
  • Bupropion / adverse effects
  • Bupropion / therapeutic use*
  • Delayed-Action Preparations
  • Developed Countries
  • Dopamine Uptake Inhibitors / administration & dosage
  • Dopamine Uptake Inhibitors / adverse effects
  • Dopamine Uptake Inhibitors / therapeutic use*
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nurses*
  • Physicians*
  • Placebos
  • Prospective Studies
  • Smoking / epidemiology
  • Smoking Cessation* / methods

Substances

  • Delayed-Action Preparations
  • Dopamine Uptake Inhibitors
  • Placebos
  • Bupropion